Quarterly UpdatesOct 16, 2026, 06:07 AM
MDxHealth Suspends 2026 Guidance on Q3 Revenue Miss
AI Summary
MDxHealth SA announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, which fell short of expectations. The company expects to report Q3 2026 revenue of approximately $22.7 million, flat compared to the prior year. Due to unexpected sales force turnover, the company is suspending its full-year 2026 revenue guidance. MDxHealth plans to provide more details on corrective actions during its Q3 earnings call on November 12.
Key Highlights
- MDxHealth SA announced preliminary Q3 2026 revenue of approximately $22.7 million.
- Q3 2026 tissue-based test volume was 11,232, down 11% YoY.
- Q3 2026 liquid-based test volume was 11,792, up significantly YoY.
- Company suspends full-year 2026 revenue guidance of $110–115 million.
- Cash and cash equivalents were approximately $31.7 million as of September 30, 2026.
- CEO cited unexpected sales force turnover due to aggressive recruiter targeting as a reason for Q3 revenue shortfall.
Price Impact
More from MDXH